<DOC>
	<DOCNO>NCT00644007</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety SK3530 men ED hypertension take antihypertensive medication .</brief_summary>
	<brief_title>Phase III Study Assess Efficacy Safety SK3530 Patients With Erectile Dysfunction Hypertension</brief_title>
	<detailed_description>SK3530 potent selective phosphdiesterase type 5 ( PDE 5 ) inhibitor develop treatment erectile dysfunction ( ED ) . Since ED common men hypertension , important determine efficacy safety SK3530 men ED take antihypertensive medication .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>Hypertension patient take stable hypertensive medication least 4 week Score 25 IIEF EF domain 4 week treatment runin period Failure rate 50 % sexual attempt 4 4 week treatment runin period Lab abnormality Uncontrolled diabetic mellitus High low blood pressure , orthostatic hypotension Hyper hypothyroidism</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Erectile dysfunction</keyword>
	<keyword>Hypertension</keyword>
	<keyword>SK3530</keyword>
</DOC>